182 related articles for article (PubMed ID: 16177258)
1. Bortezomib in multiple myeloma.
Cecchi M; Caccese E; Messori A
N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16177258
[No Abstract] [Full Text] [Related]
2. Bortezomib for myeloma -- much ado about something.
Dispenzieri A
N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Möller J; Nicklasson L; Murthy A
J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. European Journal of Haematology 2010; 85 (6):484-491.
Ishak J; Rodrigues F
Eur J Haematol; 2011 Jul; 87(1):95; author reply 96-7. PubMed ID: 21692852
[No Abstract] [Full Text] [Related]
5. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Hornberger J; Rickert J; Dhawan R; Liwing J; Aschan J; Löthgren M
Eur J Haematol; 2010 Dec; 85(6):484-91. PubMed ID: 20846301
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib in multiple myeloma.
Vandenbroucke JP; Kroep JR
N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16180272
[No Abstract] [Full Text] [Related]
7. Drug pricing: No cure, no cost.
Jack A
BMJ; 2007 Jul; 335(7611):122-3. PubMed ID: 17641343
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib for the treatment of multiple myeloma patients.
Green C; Bryant J; Takeda A; Cooper K; Clegg A; Smith A; Stephens M
Health Technol Assess; 2009 Jun; 13 Suppl 1():29-33. PubMed ID: 19567211
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib.
Paramore A; Frantz S
Nat Rev Drug Discov; 2003 Aug; 2(8):611-2. PubMed ID: 12908468
[No Abstract] [Full Text] [Related]
10. Looking beyond the headlines.
Lancet Oncol; 2007 Jul; 8(7):561. PubMed ID: 17613414
[No Abstract] [Full Text] [Related]
11. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Badros A; Gahres N
Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432
[No Abstract] [Full Text] [Related]
12. Bortezomib increases survival of patients with relapsed multiple myeloma.
Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
[No Abstract] [Full Text] [Related]
13. Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma.
Mehta J; Duff SB; Gupta S
Manag Care Interface; 2004 Sep; 17(9):52-61. PubMed ID: 15521286
[TBL] [Abstract][Full Text] [Related]
14. Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?
Franken MG; Gaultney JG; Blommestein HM; Huijgens PC; Sonneveld P; Redekop WK; Uyl-de Groot CA
Value Health; 2014 Mar; 17(2):245-53. PubMed ID: 24636383
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P;
Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588
[TBL] [Abstract][Full Text] [Related]
16. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
[TBL] [Abstract][Full Text] [Related]
17. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Vogl DT; Stadtmauer EA; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Facon T; Harousseau JL; Boral A; Neuwirth R; Anderson KC
Br J Haematol; 2009 Nov; 147(4):531-4. PubMed ID: 19725827
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition in multiple myeloma.
Kropff M; Bisping G; Wenning D; Berdel WE; Kienast J
Eur J Cancer; 2006 Jul; 42(11):1623-39. PubMed ID: 16820291
[TBL] [Abstract][Full Text] [Related]
19. Additional dexamethasone improves the response rate among patients with multiple myeloma treated with single agent bortezomib.
Cavenagh JD
Haematologica; 2006 Jul; 91(7):869B. PubMed ID: 16818270
[No Abstract] [Full Text] [Related]
20. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
Jagannath S; Durie BG; Wolf JL; Camacho ES; Irwin D; Lutzky J; McKinley M; Potts P; Gabayan AE; Mazumder A; Crowley J; Vescio R
Br J Haematol; 2009 Sep; 146(6):619-26. PubMed ID: 19622094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
